Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zealand Pharma ASZLDPF +0.96%49 Cash Ratio is 35.81 as of Mar. 2026, which is 508% above its 10-year median of 5.89. GuruFocus rates ZLDPF with a GF Score™ of 49/100. The stock has 3 warning signs investors should review. Among 1,384 Biotechnology companies, Zealand Pharma AS ranks better than 97.83% on this metric.
Zealand Pharma AS has a Cash Ratio of 35.81. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Zealand Pharma AS's Cash Ratio or its related term are showing as below:
ZLDPF'
s Cash Ratio Range Over the Past 10 Years
Min: 1.52 Med: 5.89 Max: 35.81
Current: 35.81
During the past 13 years, Zealand Pharma AS's highest Cash Ratio was 35.81. The lowest was 1.52. And the median was 5.89.
ZLDPF's Cash Ratio is ranked better than 97.83% of 1384
companies
in the Biotechnology industry
Industry Median: 2.94
vs ZLDPF: 35.81
Zealand Pharma AS (OTCPK:ZLDPF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Zealand Pharma AS Cash Ratio Related Terms
Zealand Pharma AS Cash Ratio Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zealand Pharma AS's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (ZLDPF) has a Cash Ratio of 35.81 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Zealand Pharma AS and its competitors. This is 508% above median its historical median of 5.89. Over the past decade, Zealand Pharma AS's Cash Ratio has ranged from 1.52 to 35.81. According to the industry distribution chart, Zealand Pharma AS ranks #30 out of 1384 companies in the Biotechnology industry, placing it in the top 2.2%.
Is Zealand Pharma AS's Cash Ratio too high?
Zealand Pharma AS's current Cash Ratio of 35.81 is 508% above median its 10-year median of 5.89. Over the past 10 years, this metric has ranged from a low of 1.52 to a high of 35.81. The Biotechnology industry median Cash Ratio is 2.94. Zealand Pharma AS's value of 35.81 is 1118% above this industry median. Based on the distribution chart, Zealand Pharma AS ranks #30 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #30 out of 1384 companies for Cash Ratio. This places Zealand Pharma AS in the top 2% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.94. Zealand Pharma AS's value of 35.81 is 1118% above this benchmark. Historically, Zealand Pharma AS's own Cash Ratio has ranged from 1.52 to 35.81 over the past decade. While the company's 10-year median is 5.89 vs. the industry median of 2.94, Zealand Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current Cash Ratio of 35.81 is 1118% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Cash Ratio is 35.81, which is 508% above median its own 10-year median of 5.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Zealand Pharma AS (ZLDPF) has a current Cash Ratio of 35.81. The current Cash Ratio is 35.81, which is 508% above median its 10-year median of 5.89 and 1118% above the Biotechnology industry median of 2.94. Zealand Pharma AS's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Cash Ratio is 35.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
49GF Score
Get the complete analysis for ZLDPF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
